Paraoxonase gene variants are associated with autism in North America, but not in Italy: Possible regional specificity in gene-environment interactions

Molecular Psychiatry

Volumn 10, Issue 11, 2005, Pages 1006-1016

  D'Amelio, M ^a,l   Ricci, I ^a   Sacco, R ^a,l   Liu, X ^b   D'Agruma, L ^c   Muscarella, L A ^c   Guarnieri, V ^c   Militerni, R ^d   Bravaccio, C ^d   Elia, M ^e   Schneider, C ^f   Melmed, R ^g   Trillo, S ^h   Pascucci, T ^i,l   Puglisi Allegra, S ^i,l   Reichelt, K L ^j   Macciardi, F ^k,m,n   Holden, J J A ^b,o   Persico, A M ^a,l  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b QUEEN S UNIVERSITY   (Canada)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e OASI RESEARCH INSTITUTE IRCCS   (Italy)

^f Center for Autism Research and Education   (United States)

^g Southwest Autism Research and Resource Center   (United States)

^h 'Associazione Anni Verdi' ONLUS   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF OSLO   (Norway)

^k UNIVERSITY OF TORONTO   (Canada)

^l IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^m UNIVERSITY OF MILAN   (Italy)

ⁿ Serono Genetics Institute   (France)

^o Autism Research Program   (Canada)

more..

Author keywords

APOE; Autistic disorder; Chlorpyrifos; Diazinon; Organophosphates; Reelin

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ORGANOPHOSPHATE;

ARTICLE; AUTISM; CONTROLLED STUDY; DETOXIFICATION; DISEASE TRANSMISSION; ENVIRONMENT; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYLDIALKYLPHOSPHATASE; AUTISTIC DISORDER; BASE SEQUENCE; CASE-CONTROL STUDIES; CHILD; DNA; DNA MUTATIONAL ANALYSIS; ENVIRONMENT; FEMALE; HUMANS; INSECTICIDES; ITALY; LINKAGE DISEQUILIBRIUM; MALE; MODELS, BIOLOGICAL; PEPTIDES; PHOSPHORIC ACID ESTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN; UNITED STATES; VARIATION (GENETICS);

EID: 27544476038     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001714     Document Type: Article

References (67)

1. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC, 1994.
2. Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001; 2: 943-955.
3. Persico AM, D'Agruma L, Zelante L, Militerni R, Bravaccio C, Schneider C et al. Enhanced APOE2 transmission rates in families with autistic probands. Psychiat Genet 2004; 14: 73-82.
4. Persico AM, D'Agruma L, Maiorano N, Totaro A, Militerni R, Bravaccio C et al. Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder. Mol Psychiatry 2001; 6: 150-159.
5. Pickles A, Bolton P, MacDonald H, Bailey A, Le Couteur A, Sim CH et al. Latent-class analysis of recurrence risks for complex phenotypes with selection and measurement error: a twin and family history study of autism. Am J Hum Genet 1995; 57: 717-726.
6. Keller F, Persico AM. The neurobiology of autistic disorder. Mol Neurobiol 2003; 28: 1-22.
7. Courchesne E. Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism. Curr Opin Neurobiol 1997; 7: 269-278.
8. Rodier PM, Ingram JL, Tisdale B, Nelson S, Romano J. Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J Comp Neurol 1996; 370: 247-261.
9. Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001; 49: 597-606.
10. Teitelbaum P, Teitelbaum O, Nye J, Fryman J, Maurer R. Movement analysis in infancy may be useful for early diagnosis of autism. Proc Natl Acad Sci USA 1998; 95: 13982-13987.
11. Fatemi SH. Reelin glycoprotein: structure, biology and roles in health and disease. Mol Psychiatry 2005; 10: 251-257.
12. Lugli G, Krueger JM, Davis JM, Persico AM, Keller F, Smalheiser NR. Methodological factors influencing measurement and processing of plasma reelin in humans. BMC Biochem 2003; 4: 9.
13. Quattrocchi CC, Wannenes F, Persico AM, Ciafrè SA, D'Arcangelo G, Farace MG et al. Reelin is a serine protease of the extracellular matrix. J Biol Chem 2002; 277: 303-309.
14. Kiely T, Donaldson D, Grube A. Pesticides industry sales and usage: 2000 and 2001 market estimates. US Environmental Protection Agency, Office of Pesticide Programs, Washington, DC, 2004. Available at http://www.epa.gov/ oppbead1/pestsales/index.htm.
15. Pesticides in the Environment Working Group. Monitoring of pesticides in the environment. UK Environment Agency, Bristol, UK, 2000. Available at http://www.environment-agency.gov.uk.
16. Aprea C, Strambi M, Novelli MT, Lunghini L, Bozzi N. Biologic monitoring of exposure to organophosphorus pesticides in 195 Italian children. Environ Health Perspect 2000; 108: 521-525.
17. Aprea C, Betta A, Catenacci G, Lotti A, Magnaghi S, Barisano A et al. Reference values of urinary 3,5,6-trichloro-2-pyridinol in the Italian population-validation of analytical method and preliminary results (multicentric study). J AOAC Int 1999; 82: 305-312.
18. Hill Jr RH, Head SL, Baker S, Gregg M, Shealy DB, Bailey SL et al. Pesticide residues in urine of adults living in the United States: reference range concentrations. Environ Res 1995; 71: 99-108.
19. Zhang H, Liu X, Zhang C, Mundo E, Macciardi F, Grayson D et al. Confirmation of an association between Reelin gene alleles and autism spectrum disorders. Mol Psychiatry 2002; 7: 1012-1017.
20. Skaar DA, Shao Y, Haines JL, Stenger JE, Jaworski J, Martin ER et al. Analysis of the RELN gene as a genetic risk factor for autism. Mol Psychiatry 2005; 10: 563-571.
21. Devlin B, Bennett P, Dawson G, Figlewicz GA, Grigorenko EL, McMahon W et al. Alleles of a Reelin CGG repeat do not convey liability to autism in a sample from the CPEA network. Am J Med Genet (Neuropsychiat Genet) 2004; 126B: 46-50.
22. Krebs MO, Betancur C, Leroy S, Bourdel MC, Gillberg C, Leboyer M, The Paris Autism Research International Sibpair (PARIS) Study. Absence of association between a polymorphic GGC repeat in the 5′ untranslated region of the reelin gene and autism. Mol Psychiatry 2002; 7: 801-804.
23. Bonora E, Beyer KS, Lamb JA, Parr JR, Klauck SM, Benner A et al. Analysis of reelin as a candidate gene for autism. Mol Psychiatry 2003; 8: 885-892.
24. Li J, Nguyen L, Gleason C, Lotspeich L, Spiker D, Risch N et al. Lack of evidence for an association between WNT2 and RELN polymorphisms and autism. Am J Med Genet (Neuropsychiat Genet) 2004; 126B: 51-57.
25. Fatemi SH, Snow AV, Stary JM, Araghi-Niknam M, Reutiman TJ, Lee S et al. Reelin signaling is impaired in autism. Biol Psychiatry 2005; 57: 777-787.
26. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-76.
27. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 2001; 68: 1428-1436.
28. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC et al. On the physiological role(s) of the paroxonases. Chem Biol Interact 1999; 119-120: 379-388.
29. Costa LG, Li WF, Richter RJ, Shih DM, Lusis A, Furlong CE. The role of paraoxonase (PON1) in the detoxification of organophosphates and its human polymorphism. Chem Biol Interact 1999; 119-120: 429-438.
30. Geschwind DH, Sowinski J, Lord C, Iversen P, Shestack J, Jones P et al. The autism genetic resource exchange: a resource for the study of autism and related neuropsychiatric conditions. Am J Hum Genet 2001; 69: 463-466.
31. Conciatori M, Stodgell CJ, Hyman SL, O'Bara M, Militerni R, Bravaccio C et al. Morphogenetic effect of the HOXA1 A218G polymorphism on head circumference in patients with autism. Biol Psychiatry 2004; 55: 413-419.
32. Clendenning JB, Humbert R, Green ED, Wood C, Traver D, Furlong CE. Structural organization of the human PON1 gene. Genomics 1996; 35: 586-589.
33. O'Donovan MC, Oefner PJ, Roberts SC, Austin J, Hoogendoorn B, Guy C et al. Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. Genomics 1998; 52: 44-49.
34. Piven J, Tsai G, Nehme E, Coyle JT, Chase GA, Folstein SE. Platelet serotonin, a possible marker for familial autism. J Autism Dev Disord 1991; 21: 51-59.
35. Reichelt WH, Knivsberg AM, Nodland M, Stensrud M, Reichelt KL. Urinary peptide levels and patterns in autistic children from seven countries, and the effect of dietary intervention after 4 years. Dev Brain Dysfunct 1997; 10: 44-55.
36. Spielman RS, Ewens WJ. The TDT and other family-based tests for linkage disequilibrium and association. Am J Hum Genet 1996; 59; 983-989.
37. Knapp M. The transmission/disequilibrium test and parental-genotype reconstruction: the reconstruction-combined transmission/disequilibrium test. Am J Hum Genet 1999; 64: 861-870.
38. Horvath S, Xu X, Laird NM. The family based association test method: strategies for studying general genotype-phenotype associations. Eur J Hum Genet 2001; 9: 301-306.
39. Horvath S, Xu X, Lake SL, Silverman EK, Weiss ST, Laird NM. Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol 2004; 26: 61-69.
40. Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995; 56: 799-810.
41. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20: 516-521.
42. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004; 363: 689-695.
43. Chen J, Kumar M, Chan W, Berkowitz G, Wetmur JG. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 2003; 111: 1403-1409.
44. Rodrigo L, Mackness B, Durrington PN, Hernandez A, Mackness MI. Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 2001; 354: 1-7.
45. Van Gent T, Heijnen CJ, Treffers PD. Autism and the immune system. J Child Psychol Psychiatry 1997; 38: 337-349.
46. International Molecular Genetic Study of Autism Consortium. Further characterization of the autism susceptibility locus AUTS1 on chromosome 7q. Hum Mol Genet 2001; 10: 973-982.
47. Landrigan PJ, Claudio L, Markowitz SB, Berkowitz GS, Brenner BL, Romero H et al. Pesticides and inner-city children: exposures, risks, and prevention. Environ Health Perspect 1999; 107(Suppl 3): 431-437.
48. Whyett RM, Barr DB. Measurement of organophosphate metabolites in postpartum meconium as a potential biomarker of prenatal exposure: a validation study. Environ Health Prospect 2001; 109; 417-420.
49. Whyatt RM, Camann DE, Kinney PL, Reyes A, Ramirez J, Dietrich J et al. Residential pesticide use during pregnancy among a cohort of urban minority women. Environ Health Perspect 2002; 110: 507-514.
50. Whyatt RM, Barr DB, Camann DE, Kinney PL, Barr JR, Andrews HF et al. Contemporary-use pesticides in personal air samples during pregnancy and blood samples at delivery among urban minority mothers and newborns. Environ Health Perspect 2003; 111: 749-756.
51. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM et al. Expression of human paraoxonase (PON1) during development. Pharmacogenetics 2003; 13: 357-364.
52. Wilson NK, Chuang JC, Lyu C, Menton R, Morgan MK. Aggregate exposures of nine preschool children to persistent organic pollutants at day care and at home. J Expo Anal Environ Epidemiol 2003; 13: 187-202.
53. Qiao D, Seidler FJ, Tate CA, Cousins MM, Slotkin TA. Fetal chlorpyrifos exposure: adverse effects on brain cell development and cholinergic biomarkers emerge postnatally and continue into adolescence and adulthood. Environ Health Perspect 2003; 111: 536-544.
54. Ricceri L, Markina N, Valanzano A, Fortuna S, Cometa MF, Meneguz A et al. Developmental exposure to chlorpyrifos alters reactivity to environmental and social cues in adolescent mice. Toxicol Appl Pharmacol 2003; 191: 189-201.
55. Aldridge JE, Seidler FJ, Meyer A, Thillai I, Slotkin TA. Serotonergic systems targeted by developmental exposure to chlorpyrifos: effects during different critical periods. Environ Health Perspect 2003; 111: 1736-1743.
56. Dam K, Seidler FJ, Slotkin TA. Developmental neurotoxicity of chlorpyrifos: delayed targeting of DNA synthesis after repeated administration. Dev Brain Res 1998; 108: 39-45.
57. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9: 745-753.
58. 55 genotype. Arterioscl Thromb Vasc Biol 2000; 20: 2441-2447.
59. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in 'low-functioning' autistic children: a pilot study. Biol Psychiatry 1999; 46: 420-424.
60. Hérault J, Petit E, Martineau J, Cherpi C, Perrot A, Barthélémy C et al. Serotonin and autism: biochemical and molecular biology features. Psychiatry Res 1996; 65: 33-43.
61. Persico AM, Pascucci T, Puglisi-Allegra S, Militerni R, Bravaccio C, Schneider C et al. Serotonin transporter promoter variants do not explain the hyperserotoninemia in autistic children. Mol Psychiatry 2002; 7: 795-800.
62. 3H- serotonin uptake by platelets in infantile autism and developmental language disorder (including five pairs of twins). J Autism Dev Disord 1986; 16: 69-76.
63. Marazziti D, Muratori F, Cesari A, Masala I, Baroni S, Giannaccini G et al. Increased density of the platelet serotonin transporter in autism. Pharmacopsychiatry 2000; 33: 165-168.
64. Cook Jr EH, Leventhal BL, Freedman DX. Free serotonin in plasma: autistic children and their first-degree relatives. Biol Psychiatry 1988; 24: 488-491.
65. Aldridge JE, Seidler FJ, Slotkin TA. Developmental exposure to chlorpyrifos elicits sex-selective alterations of serotonergic synaptic function in adulthood: critical periods and regional selectivity for effects on the serotonin transporter, receptor subtypes, and cell signaling. Environ Health Perspect 2004; 112: 148-155.
66. Sachana M, Flaskos J, Nikolaidis E, Hargreaves A, Alexaki-Tzivanidou E. Inhibition of rat platelet 5-hydroxytryptamine uptake by chlorpyrifos and carbaryl. Pharmacol Toxicol 2001; 89: 195-200.
67. Li W-F, Li WF, Costa LG, Richter RJ, Hagen T, Shih DM et al. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics 2000; 10: 767-779.